The MYG1 Knockout AGS Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal population derived from AGS human gastric adenocarcinoma epithelial cells, engineered for targeted disruption of the MYG1 gene. This loss-of-function model provides a heterogeneous pool of gene-edited cells, enabling robust functional studies without the selective pressures of clonal isolation. The resulting MYG1-deficient cell population serves as a powerful tool for dissecting mitochondrial apoptotic signaling and p53-mediated tumor suppression pathways in a gastric cancer context.
The parental AGS cell line is a widely employed adherent epithelial model originally established from a human gastric adenocarcinoma. AGS cells are extensively utilized in cancer research for investigating gastric carcinogenesis, drug sensitivity, and Helicobacter pylori pathogenesis. Their well-characterized biology and reproducible growth characteristics make them an ideal host for CRISPR/Cas9-mediated gene editing, facilitating the generation of loss-of-function models that retain physiological relevance for gastric cancer studies.
MYG1 encodes a mitochondrial protein that is transcriptionally upregulated by the p53 tumor suppressor in response to genotoxic stress signals. MYG1 functions within the intrinsic apoptosis pathway by promoting mitochondrial outer membrane permeabilization, which leads to cytochrome c release into the cytoplasm and subsequent activation of caspase-9 and caspase-3. Mechanistically, MYG1 is proposed to interact with pro-apoptotic factors such as Bax and may modulate Bcl-2 family protein dynamics at the mitochondrial membrane, thereby coupling p53-dependent transcriptional programs to the execution of programmed cell death.
In the AGS gastric adenocarcinoma context, MYG1 is implicated as a tumor-suppressive factor, and its disruption impairs p53-mediated apoptotic signaling, potentially enhancing cell survival under chemotherapeutic or genotoxic challenges. The MYG1 Knockout AGS Polyclonal Cells therefore enable detailed dissection of how mitochondrial apoptotic checkpoints are bypassed in gastric cancer. Comparative studies between wild-type AGS and this knockout population can reveal the specific contributions of MYG1 to cell death sensitivity, proliferation control, and mitochondrial integrity, offering insights into mechanisms of chemoresistance.
Key applications of this knockout model include dissecting p53-dependent apoptosis in gastric cancer, investigating mitochondrial regulators of cell death, and screening for agents that restore apoptotic sensitivity in chemoresistant cells. Experimental approaches such as cell viability assays (MTT, CCK-8), Annexin V/PI flow cytometry, JC-1 mitochondrial membrane potential measurements, colony formation assays, and western blot analysis of key pathway components (p53, MYG1, Bax, cytochrome c) are readily employed. RT-qPCR can be used to confirm MYG1 transcript disruption. For additional technical details and ordering information, please contact Ascent Research.
